Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon, Stemina Settle Patent Infringement Litigation, Reach Licensing Agreement

NEW YORK (GenomeWeb News) – Metabolon and Stemina Biomarker Discovery today announced they have settled their patent infringement dispute and reached a licensing agreement.

Metabolon sued Stemina a year ago in US District Court, Western District of Wisconsin alleging infringement of US Patent Nos. 7,550,258 and 7,910,301. Both patents are titled "Methods for drug discovery, disease treatment, and diagnosis using metabolomics," and the inventors assigned the rights to the patents to Metabolon and the Cornell Research Foundation.

The two companies reached their settlement last month, according to court documents, and Stemina was awarded $15,000 "in full settlement of and in lieu of the costs awarded to Stemina" earlier by the court.

Metabolon is licensing technology to Stemina as part of the licensing deal, Metabolon President and CEO John Ryals told GenomeWeb Daily News. Further terms were not disclosed.

Stemina CEO Elizabeth Donley said in a statement that with the litigation settled, her company will focus on ongoing autism studies and raising money "to accelerate the pace to market for Stemina's blood test for autism, as well as putting the final details together on a large contract with the [US] Environmental Protection Agency."